Opdivo

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

Opdivo (nivolumab).

AstraZeneca’s Imfinzi fails first-line bladder cancer test

inhibitors including Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck KGaA/Pfizer’s Bavencio (avelumab).

Putting commercial intelligence at the heart of strategy

Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting

BMS partners with Voluntis to co-develop oncology digital therapeutics

Although not stated in the news announcement, that could include BMS’ checkpoint inhibitor Opdivo (nivolumab), which is indicated for use across a number of cancer types.

Modest meeting sees only two drugs recommended by CHMP

The CHMP also noted the withdrawal of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (iplimumab) application, which was seeking marketing authorisation in first-line metastatic non-small cell lung cancer.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]